Fusion Pharmaceuticals FPI-1434 Phase 1 Data Update 2023

Fusion Pharmaceuticals presents Phase 1 data update for FPI-1434, a radiopharmaceutical candidate targeting IGF-1R in solid tumors. The presentation outlines the company's radiopharmaceutical platform spanning discovery through Phase 3 development, including multiple oncology programs targeting validated and novel targets with potential applications in antibody drug conjugate development.